NATESTO (testosterone) Acerus Patent: 8,784,869 Expiration: Feb 4, 2024 See More … For more information on how DrugPatentWatch can help […]
Drug Patent Expirations for the Week of February 4, 2024 Read Post »
Annual Drug Patent Expirations for NATESTO Natesto is a drug marketed by Acerus and is included in one NDA. It
Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Sumitomo Pharma and is included in one NDA.
New patent expiration for Sumitomo Pharma drug ORGOVYX Read Post »
NATESTO (testosterone) Acerus Patent: 8,877,230 Expiration: Feb 4, 2024 See More … For more information on how DrugPatentWatch can help
Drug Patent Expirations for the Week of February 4, 2024 Read Post »
Annual Drug Patent Expirations for EVOCLIN Evoclin is a drug marketed by Mylan and is included in one NDA. There
Annual Drug Patent Expirations for NOCDURNA Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one
New patent expiration for Ferring Pharms drug NOCDURNA Read Post »
Annual Drug Patent Expirations for CHLORAPREP+WITH+TINT Chloraprep With Tint is a drug marketed by Becton Dickinson Co and is included
New patent expiration for Becton Dickinson drug CHLORAPREP WITH TINT Read Post »
Annual Drug Patent Expirations for CHLORAPREP+ONE-STEP Chloraprep One-step is a drug marketed by Becton Dickinson Co and is included in
New patent expiration for Becton Dickinson drug CHLORAPREP ONE-STEP Read Post »
Annual Drug Patent Expirations for OMIDRIA Omidria is a drug marketed by Rayner Surgical and is included in one NDA.
New patent expiration for Rayner Surgical drug OMIDRIA Read Post »
Get fresh news and insights, drug patent expirations & more…
